Filter your results
- 3
- 3
- 3
- 1
- 2
- 3
- 2
- 2
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
Managing Drug-Drug Interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate MofetilTherapeutic Drug Monitoring, 2017, 39 (4), pp.305-307. ⟨10.1097/FTD.0000000000000397⟩
Journal articles
hal-01614699v1
|
|||
Managing drug-drug interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir and Mycophenolate mofetilFundamental & Clinical Pharmacology, 2016, 30, pp.85--85
Journal articles
hal-01310757v1
|
|||
|
Rare HFE variants are the most frequent cause of hemochromatosis in non-c282y homozygous patients with hemochromatosisAmerican Journal of Hematology, 2016, 91 (12), pp.1202--1205. ⟨10.1002/ajh.24535⟩
Journal articles
hal-01427007v1
|